The Overview: December 2021
This time of year always has us reflecting on what we’ve accomplished, what we hope to achieve in the future, and how we — with the support of the entire ovarian cancer … Continued
News
OCRA-Funded Research Identifies New “Master” Drug Targets for Ovarian Cancer
An interdisciplinary group of researchers from around the country analyzed tumor samples from nearly 10,000 patients with 34 types of cancer to reveal unique genetic switches associated with each tumor … Continued
Liya Ding, PhD | Meet a Scientist
Dr. Liya Ding, of Dana-Farber Cancer Institute, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With her project, “Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer,” … Continued
FDA Approves Drug to Identify Ovarian Cancer Lesions During Surgery
In what could prove to be a game-changer for ovarian cancer debulking procedures, the U.S. Food and Drug Administration (FDA) has approved Cytalux (pafolacianine), an imaging drug designed to help … Continued
Bojana Stefanovska, PhD | Meet a Scientist
Dr. Bojana Stefanovska, at University of Minnesota Twin Cities, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. Her project, “APOBEC3B and DNA Repair as Synthetic … Continued
The Overview: November 2021
As we head into the Thanksgiving holiday, we have much to be thankful for … an embracing and strong survivor community, supporters who remain ever committed to the cause, and … Continued
OCRA-Funded Study Points to New Approach to Improve Ovarian Cancer Treatment
The following is a press release from University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, and Magee-Womens Research Institute PITTSBURGH, Nov. 12, 2021 – Immune checkpoint inhibitors are a … Continued
The Overview: October 2021
Have we got a roundup in store! You heard from us a lot in September (thanks to you, we surpassed our Ovarian Cancer Awareness Month fundraising goal!) and there’s still … Continued
Study Finds Germline Ovarian Cancer Mutations Occur Equally in Black and White Patients
A recent study has shed more light on the demographics of hereditary ovarian cancer, and provides further data to suggest an urgent need for increased genetic counseling for potentially high-risk … Continued
Finding the Story in the Data | Meet a Scientist
Sridevi Challa, PhD, an OCRA grantee at UT Southwestern, is on the receiving end of some major accolades. She is the lead author of a study that dozens of news … Continued
OCRA-Funded Study Identifies Role of Deubiquitinating Enzyme in Ovarian Cancer Progression
OCRA grantee Dr. Sumegha Mitra of Indiana University and colleagues have identified the mechanism by which a specific deubiquitinating enzyme known as UCHL1 promotes the growth of high-grade serous ovarian cancer in … Continued
Groundbreaking Initiative Seeks to Accelerate Development of New Treatments with OCRA’s Support
LOS ANGELES – (BUSINESS WIRE)–Global Coalition for Adaptive Research (GCAR) announces a new clinical trial initiative, Ovarian CanceRxTM. This innovative trial, referred to as an adaptive platform trial, is designed to … Continued